Richard S Schottenfeld1, Marek C Chawarski2, Joseph F Cubells3, Tony P George4, Jaakko Lappalainen2, Thomas R Kosten5. 1. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States. Electronic address: richard.schottenfeld@yale.edu. 2. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States. 3. Departments of Genetics and Psychiatry and Behavioral Sciences, Emory University School of Medicine, United States. 4. Division of Brain and Therapeutics, Department of Psychiatry, University of Toronto, Faculty of Medicine, Canada. 5. Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine and Michael E. DeBakey VA Medical Center, United States.
Abstract
BACKGROUND:Disulfiram may be efficacious for treating cocaine dependence or abuse, possibly through inhibiting dopamine β-hydroxylase (DβH). Consequently, this randomized, placebo-controlled clinical trial of disulfiram during buprenorphine maintenance treatment evaluated the study hypothesis that disulfiram is superior to placebo and explored whether disulfiram response is greatest for participants with a single nucleotide polymorphism coding for genetically low DβH (T-allele carriers). METHODS: We randomized 177 buprenorphine-treated opioiddependent participants with cocaine dependence or abuse to 12 weeks of double-blind treatment withdisulfiram 250mg daily (n=91) or placebo (n=86). Of 155 participants genotyped, 84 were CC-homozygous, and 71 CT or TT genotypes. Primary outcomes included days per week cocaine use, number of cocaine-negative urine tests, and maximum consecutive weeks of cocaine abstinence. We analyzed an intention-to-treat comparison between disulfiram and placebo. We also explored potential pharmacogenetic interactions and examined treatment responses of four participant groups based on medication (disulfiram or placebo) by genotype (CC-homozygous or T-allele carrier) classification. RESULTS:Disulfiram participants reported significantly less frequent cocaine use; the differences in cocaine-negative urine tests or consecutive weeks abstinence were not significant. Frequency of cocaine use was lowest in disulfiram-treated T-allele carriers; differences in cocaine-negative urine tests or consecutive weeks abstinence were not significant among the four medication-genotype groups. CONCLUSIONS: The findings provide limited support for the efficacy of disulfiram for reducing cocaine use and suggest that its mechanism of action may involve inhibition of DβH. Further studies of its efficacy, mechanism of action, and pharmacogenetics of response are warranted.
RCT Entities:
BACKGROUND:Disulfiram may be efficacious for treating cocaine dependence or abuse, possibly through inhibiting dopamine β-hydroxylase (DβH). Consequently, this randomized, placebo-controlled clinical trial of disulfiram during buprenorphine maintenance treatment evaluated the study hypothesis that disulfiram is superior to placebo and explored whether disulfiram response is greatest for participants with a single nucleotide polymorphism coding for genetically low DβH (T-allele carriers). METHODS: We randomized 177 buprenorphine-treated opioid dependent participants with cocaine dependence or abuse to 12 weeks of double-blind treatment with disulfiram 250mg daily (n=91) or placebo (n=86). Of 155 participants genotyped, 84 were CC-homozygous, and 71 CT or TT genotypes. Primary outcomes included days per week cocaine use, number of cocaine-negative urine tests, and maximum consecutive weeks of cocaine abstinence. We analyzed an intention-to-treat comparison between disulfiram and placebo. We also explored potential pharmacogenetic interactions and examined treatment responses of four participant groups based on medication (disulfiram or placebo) by genotype (CC-homozygous or T-allele carrier) classification. RESULTS:Disulfiramparticipants reported significantly less frequent cocaine use; the differences in cocaine-negative urine tests or consecutive weeks abstinence were not significant. Frequency of cocaine use was lowest in disulfiram-treated T-allele carriers; differences in cocaine-negative urine tests or consecutive weeks abstinence were not significant among the four medication-genotype groups. CONCLUSIONS: The findings provide limited support for the efficacy of disulfiram for reducing cocaine use and suggest that its mechanism of action may involve inhibition of DβH. Further studies of its efficacy, mechanism of action, and pharmacogenetics of response are warranted.
Authors: Xuefeng Zhang; David A Nielsen; Coreen B Domingo; Daryl I Shorter; Ellen M Nielsen; Thomas R Kosten Journal: Addict Biol Date: 2018-03-02 Impact factor: 4.280
Authors: June P Kampangkaew; Catherine J Spellicy; Ellen M Nielsen; Mark J Harding; An Ye; Sara C Hamon; Thomas R Kosten; David A Nielsen Journal: Am J Addict Date: 2019-05-14
Authors: Marc E Mooney; David V Herin; Sheila Specker; David Babb; Frances R Levin; John Grabowski Journal: Drug Alcohol Depend Date: 2015-06-19 Impact factor: 4.492
Authors: Richard De La Garza; Marcy J Bubar; Crystal L Carbone; F Gerard Moeller; Thomas F Newton; Noelle C Anastasio; Tod A Harper; David L Ware; Michael A Fuller; Gaylyn J Holstein; Jason B Jayroe; Stephen I Bandak; Kirsten Z Reiman; Ann C Neale; Lesley B Pickford; Kathryn A Cunningham Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2015-01-17 Impact factor: 5.067
Authors: Bryon Adinoff; Thomas J Carmody; Robrina Walker; Dennis M Donovan; Gregory S Brigham; Theresa M Winhusen Journal: Am J Drug Alcohol Abuse Date: 2016-01-08 Impact factor: 3.829
Authors: Brian Chan; Karli Kondo; Michele Freeman; Chelsea Ayers; Jessica Montgomery; Devan Kansagara Journal: J Gen Intern Med Date: 2019-06-10 Impact factor: 5.128